Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders

Future Med Chem. 2019 Apr;11(8):847-855. doi: 10.4155/fmc-2018-0313. Epub 2019 Apr 17.

Abstract

Gastrointestinal illnesses pose a significant worldwide disease burden and are associated with an array of medicinal and surgical therapies. Standard pharmaceutical options have adverse effects, prompting the rise of nutraceutical or food-derivative therapies. Here, we present an overview of the current nutraceutical therapies in gastrointestinal disease. We then introduce the calcium-sensing receptor (CaSR) as a novel therapeutic target. A G-protein-coupled receptor found in apical and basal intestinal cells, the CaSR modulates intestinal fluid secretion and mucosal integrity. Applying nutraceuticals that upregulate the CaSR may alleviate symptoms seen across a spectrum of illnesses. At last, we discuss how nanoparticle technology can be implemented to effectively deliver nutraceuticals to diseased regions of the intestine, thereby minimizing systemic side effects.

Keywords: calcium-sensing receptor; gastrointestinal disorders; inflammation; nanoparticles; nutraceutical; pharmaceutical.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Dietary Supplements* / analysis
  • Gastrointestinal Diseases / metabolism
  • Gastrointestinal Diseases / pathology
  • Gastrointestinal Diseases / therapy*
  • Humans
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / pathology
  • Models, Molecular
  • Nanoparticles / therapeutic use
  • Receptors, Calcium-Sensing / metabolism

Substances

  • Receptors, Calcium-Sensing